Literature DB >> 15019934

Successful perioperative management of factor X deficiency associated with primary amyloidosis.

Kazuaki Takabe1, Peter R Holman, Kenneth D Herbst, Catherine A Glass, Michael Bouvet.   

Abstract

Acquired bleeding abnormalities are common in patients with primary amyloid light-chain amyloidosis. Factor X deficiency is the most common coagulopathy associated with life-threatening hemorrhagic complications when surgery is indicated. Fresh-frozen plasma (FFP) or prothrombin complex concentrates (PCCs) are the most frequently used blood products in this disease; however, FFP is often ineffective in controlling bleeding and PCCs have a significant risk of thrombosis when used intraoperatively. This report describes a patient with primary amyloidosis and factor X deficiency who underwent hemicolectomy with preoperative and intraoperative administration of recombinant human factor VIIa and postoperative administration of Bebulin (a PCC that contains the highest concentration of factor X). The management was successful with no signs of bleeding postoperatively. To our knowledge, few reports of successful perioperative management of factor X deficiency have been published to date. This is the first case report using recombinant human factor VIIa and Bebulin in the perioperative management of factor X deficiency associated with primary amyloidosis. Recombinant human factor VIIa and Bebulin may allow for successful perioperative management of bleeding disorders in patients with primary amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019934     DOI: 10.1016/j.gassur.2003.10.014

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  29 in total

Review 1.  An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Authors:  V Sanchorawala; D G Wright; D C Seldin; L M Dember; K Finn; R H Falk; J Berk; K Quillen; M Skinner
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

2.  Bleeding diathesis in amyloidosis with renal insufficiency associated with Crohn's disease: response to desmopressin.

Authors:  Sandeep P Dave; Adrian J Greenstein; David B Sachar; Noam Harpaz; Louis Aledort
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

3.  Amyloidosis-induced gastrointestinal bleeding in a patient with multiple myeloma.

Authors:  S S Chang; C L Lu; S H Tsay; F Y Chang; S D Lee
Journal:  J Clin Gastroenterol       Date:  2001-02       Impact factor: 3.062

4.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

5.  Mechanism of factor X deficiency in systemic amyloidosis.

Authors:  B Furie; L Voo; K P McAdam; B C Furie
Journal:  N Engl J Med       Date:  1981-04-02       Impact factor: 91.245

6.  Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.

Authors:  B Furie; E Greene; B C Furie
Journal:  N Engl J Med       Date:  1977-07-14       Impact factor: 91.245

7.  Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis.

Authors:  A D Mumford; J O'Donnell; J D Gillmore; R A Manning; P N Hawkins; M Laffan
Journal:  Br J Haematol       Date:  2000-08       Impact factor: 6.998

Review 8.  Amyloidosis--an unusual case of recurrent intestinal bleeding and sigmoid perforation: case report with review of the literature.

Authors:  W Thaler; G Schatzer; P Eder; G Fichtel
Journal:  Int J Colorectal Dis       Date:  1999-12       Impact factor: 2.571

Review 9.  Factor-X deficiency in amyloidosis: a critical review.

Authors:  P R Greipp; R A Kyle; E J Bowie
Journal:  Am J Hematol       Date:  1981-12       Impact factor: 10.047

Review 10.  Amyloidosis and factor X deficiency.

Authors:  K D Zeitler; P M Blatt
Journal:  South Med J       Date:  1982-03       Impact factor: 0.954

View more
  7 in total

1.  Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.

Authors:  Carrie A Thompson; Robert Kyle; Morie Gertz; John Heit; Rajiv Pruthi; Animesh Pardanani
Journal:  Am J Hematol       Date:  2010-03       Impact factor: 10.047

2.  Genetic analysis of a compound heterozygous patient with congenital factor X deficiency and regular replacement therapy with a prothrombin complex concentrate.

Authors:  Tomoki Togashi; Satomi Nagaya; Masayuki Nagasawa; Makiko Meguro-Horike; Keiji Nogami; Yuta Imai; Kana Kuzasa; Akiko Sekiya; Shin-Ichi Horike; Hidesaku Asakura; Eriko Morishita
Journal:  Int J Hematol       Date:  2019-10-30       Impact factor: 2.490

3.  Surgical treatment for a paraplegic patient induced by congenital factor X deficiency.

Authors:  Weicheng Lin; Jing Zhou; Tianbing Wang; Peixun Zhang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  Membranoproliferative glomerulonephritis and a rare bleeding disorder: Factor X deficiency.

Authors:  T Basturk; E Ahbap; B Eroglu Kesim; M Yılmaz; Y Koç; T Sakacı; A Unsal
Journal:  Int Urol Nephrol       Date:  2010-09-23       Impact factor: 2.370

5.  AL Amyloidosis Complicated by Persistent Oral Bleeding.

Authors:  Luiz Antonio Liarte Marconcini; Forrest Marc Stewart; Lisa Sonntag; Emily Stevens; Nicholas Burwick
Journal:  Case Rep Hematol       Date:  2015-05-07

6.  [Primary light chain amyloidosis onset with acquired FX deficiency: a case report and literature review].

Authors:  C Wei; J Feng; T N Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

Review 7.  Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data.

Authors:  Christian von Heymann; Sven Jonas; Claudia Spies; Klaus-Dieter Wernecke; Sabine Ziemer; Detlev Janssen; Jürgen Koscielny
Journal:  Crit Care       Date:  2008-02-15       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.